Cellular Dynamics and Roche (RHHBY) Expand Existing Cardiotoxicity Screening Agreement

FREE Breaking News Alerts from StreetInsider.com!

More News related to RHHBY

Roche disappointed by the actions of Illumina, Inc.’s Board of Directors
FDA Grants Genentech’s Pertuzumab Priority Review for Previously Untreated HER2-Positive Metastatic Breast Cancer
Citi Maintains a 'Neutral' on Regeneron Pharma (REGN); Doctors Consider Eylea as Replacement for Roche's Lucentis
Roche Receives FDA Clearance for Test to Screen and Diagnose Chlamydia and Gonorrhea Infection in Symptomatic and Asymptomatic Patients
Illumina (ILMN) CEO Flatley Thinks Board is 'Highly Qualified'

More News related to Corporate News

July 1, 2009 12:59 PM EDT

Cellular Dynamics International (CDI) and Roche (OTC: RHHBY) announced a significant expansion of their existing agreement to test drug development candidates for their potential to cause cardiotoxicity, or damage to heart tissue. The two-year collaboration aims to enhance drug safety testing in order to bring promising therapies to patients faster.

Under this agreement, CDI will supply purified cardiomyocytes, created from induced pluripotent stem cells (iPSCs), to Roche, and the two companies will collaborate to perform various cell characterization, toxicological, and electrophysiological response experiments. The agreement also includes an ongoing cardiomyocyte supply contract post collaboration.[SM]